MakeMyTrip Ltd vs Tilray Brands Inc — how do they compare? MakeMyTrip Ltd trades at $56.43 (market cap $5.05B), while Tilray Brands Inc trades at $4.25 (market cap $524.07M). The key difference: MakeMyTrip Ltd is far larger — about 9.6× Tilray Brands Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| MMYT | TLRY | |
|---|---|---|
Market Cap | $5.05B | $524.07M |
Sector | Technology | Health |
52-Week High | $103.21 | $21.00 |
52-Week Low | $36.30 | $4.23 |
Enterprise Value | $5.69B | $621.22M |
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.25 beating expectations of $0.17. Revenue reached $978.34 million in 2025 with a 73.77% gross margin, though 2026 projections indicate margin compression. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target.
The stock presents a growth opportunity with strong operational performance but faces risks from travel disruptions and rising debt levels. While current valuation metrics appear elevated (P/E 147.78), the company's market leadership in Indian online travel and consistent execution support the bullish case. Key risks include competitive pressures and macroeconomic sensitivity to travel demand.
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Trailing returns across standard periods
Latest headlines on both assets
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →